All In Biotech

Drug Trial Radar · NCT00279448

Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer

Multicenter, Randomized, Open-Label Study To Compare The Efficacy, Tolerance And Quality Of Life Of 5 Years Of Adjuvant Exemestane (Aromasin) Therapy With 2.5 To 3 Years Of Adjuvant Tamoxifen Therapy, Followed By 2 To 2.5 Years Of Exemestane For A Total Duration Of 5 Years To Treat HR+ Post-Menopausal Patients With Non-Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Dec 23, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 9,779 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

9,779

Actual

Start

Jan 2002

Primary completion

Nov 2008

Study completion Jun 2009

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jan 19, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare recurrence free survival between two treatment groups (5 years with exemestane vs 2.5 to 3 years tamoxifen followed by 2 to 2.5 years of exemestane for a total duration of 5 years) This Pfizer sponsored trial is part of an international collaboration of investigators conducting 7 similar yet independent studies in 9 countries. This study is designed to be part of the larger TEAM trial where the data from these 7 studies will be combined. A pre-specified analysis of the pooled data will be conducted. Link to TEAM Trial \[971-ONC-0028-081/A5991026\] Study Results: http://clinicaltrials.gov/ct2/show/results/NCT00036270?term=971-ONC-0028-081\&rank=1

Conditions

  • Breast Neoplasms

Interventions

  • exemestaneDrug

    On tablet of 25 mg per day during 5 years

  • tamoxifenDrug

    Two tablets of tamoxifen 10 mg per day during 2.5 to 3 years followed by one tablet of exemestane 25 mg per day during 2 to 2.5 years for a total duration of 5 years of treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare recurrence free survival between two treatment groups.Time frame: 2.75 years and 5 years

Locations

59 sites in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Aix-en-Provence, France

  • Pfizer Investigational Site

    Amiens, France

  • Pfizer Investigational Site

    Annecy, France

  • Pfizer Investigational Site

    Avignon, France

  • Pfizer Investigational Site

    Bayonne, France

  • Pfizer Investigational Site

    Blois, France

  • Pfizer Investigational Site

    Bordeaux, France

  • Pfizer Investigational Site

    Bordeaux, France

  • Pfizer Investigational Site

    Brest, France

  • Pfizer Investigational Site

    Cagne Sur Mer, France

  • Pfizer Investigational Site

    Chalon-sur-Saône, France

  • Pfizer Investigational Site

    Chaumont, France

  • Pfizer Investigational Site

    Croix, France

  • Pfizer Investigational Site

    Dijon, France

  • Pfizer Investigational Site

    Douai, France

  • Pfizer Investigational Site

    Draguignan, France

  • Pfizer Investigational Site

    Dunkirk, France

  • Pfizer Investigational Site

    Évreux, France

  • Pfizer Investigational Site

    Hyres, France

  • Pfizer Investigational Site

    L'Union, France

  • Pfizer Investigational Site

    Le Havre, France

  • Pfizer Investigational Site

    Lille, France

  • Pfizer Investigational Site

    Lorient, France

  • Pfizer Investigational Site

    Lyon, France

  • Pfizer Investigational Site

    Mareuil-lès-Meaux, France

  • Pfizer Investigational Site

    Marseille, France

  • Pfizer Investigational Site

    Marseille, France

  • Pfizer Investigational Site

    Marseille, France

  • Pfizer Investigational Site

    Metz, France

  • Pfizer Investigational Site

    Montauban, France

  • Pfizer Investigational Site

    Montbéliard, France

  • Pfizer Investigational Site

    Montélimar, France

  • Pfizer Investigational Site

    Montpellier, France

  • Pfizer Investigational Site

    Mougins, France

  • Pfizer Investigational Site

    Nancy, France

  • Pfizer Investigational Site

    Nantes, France

  • Pfizer Investigational Site

    Neuilly, France

  • Pfizer Investigational Site

    Nice, France

  • Pfizer Investigational Site

    Nîmes, France

  • Pfizer Investigational Site

    Paris, France

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.